• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS FERRITIN; RADIOIMMUNOASSAY (TWO-SITE SOLID PHASE), FERRITIN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS FERRITIN; RADIOIMMUNOASSAY (TWO-SITE SOLID PHASE), FERRITIN Back to Search Results
Catalog Number 03737551190
Device Problem Non Reproducible Results (4029)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 09/25/2018
Event Type  malfunction  
Manufacturer Narrative
This event occurred in (b)(6).
 
Event Description
The customer questioned results for 1 neonatal patient tested for elecsys ferritin (ferritin) on a cobas 8000 e 602 module.Thirty minutes after being born on (b)(6) 2018, the patient presented with neurological degradation with hypotonia, severe hypoglycemia and hepatocellular insufficiency.At 12:25 a.M.On (b)(6) 2018 the patient was tested for ferritin and the result was 57,907 ug/l suggesting hyperferritinemia.The evening of (b)(6) 2018 biotin treatment was started based on a potential metabolic disease.On (b)(6) 2018 at 5:30 a.M.A new sample was obtained and the ferritin result had decreased to 90 ng/l.The rest of the test results were consistent with the results from (b)(6) 2018.The customer suspects an interference with biotin affecting the ferritin results.There was no allegation that an adverse event occurred.The e602 module serial number was (b)(4).
 
Manufacturer Narrative
Multiple requests were made for additional information.No further information was provided.The customer did not want to send in the patient sample.Since no sample was submitted, the investigation could not be completed.Product labeling states "the assay is unaffected by biotin levels < 250 nmol/l or < 50 ng/ml.Samples should not be taken from patients receiving therapy with high biotin doses (i.E.> 5 mg/day) until at least 8 hours following the last biotin administration." the investigation did not identify a product problem.The cause of the event could not be determined.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS FERRITIN
Type of Device
RADIOIMMUNOASSAY (TWO-SITE SOLID PHASE), FERRITIN
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
MDR Report Key8129707
MDR Text Key129518430
Report Number1823260-2018-04621
Device Sequence Number1
Product Code JMG
Combination Product (y/n)N
PMA/PMN Number
K971833
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 12/19/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number03737551190
Device Lot NumberASKU
Was Device Available for Evaluation? Yes
Initial Date Manufacturer Received 11/13/2018
Initial Date FDA Received12/04/2018
Supplement Dates Manufacturer Received11/13/2018
Supplement Dates FDA Received12/19/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Age1 DA
-
-